Author's Accepted Manuscript

Abediterol (LAS100977), an inhaled long-acting β₂-adrenoceptor agonist, has a fast association rate and long residence time at receptor

Israel Ramos, Mònica Aparici, Maria Letosa, Carlos Puig, Amadeu Gavaldà, Josep Maria Huerta, Sonia Espinosa, Dolors Vilella, Montserrat Miralpeix



ww.elsevier.com/locate/eiphar

PII: S0014-2999(17)30776-8

DOI: https://doi.org/10.1016/j.ejphar.2017.11.043

EJP71539 Reference:

European Journal of Pharmacology To appear in:

Received date: 25 July 2017

Revised date: 21 November 2017 Accepted date: 24 November 2017

Cite this article as: Israel Ramos, Mònica Aparici, Maria Letosa, Carlos Puig, Amadeu Gavaldà, Josep Maria Huerta, Sonia Espinosa, Dolors Vilella and Montserrat Miralpeix, Abediterol (LAS100977), an inhaled long-acting β2adrenoceptor agonist, has a fast association rate and long residence time at receptor, European Journal of Pharmacology, https://doi.org/10.1016/j.ejphar.2017.11.043

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Abediterol (LAS100977), an inhaled long-acting β_2 -adrenoceptor agonist, has a fast association rate and long residence time at receptor.

Israel Ramos, Mònica Aparici, Maria Letosa, Carlos Puig, Amadeu Gavaldà, Josep Maria Huerta, Sonia Espinosa, Dolors Vilella, Montserrat Miralpeix.

Almirall, R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain.

*Corresponding author: Israel Ramos, israel_ramos75@hotmail.com, Tel:+34647660231.

ABSTRACT

This study describes the association rate and residence time of abediterol, a novel long-acting β_2 -adrenoceptor agonist (LABA) in Phase II development for treatment of asthma and COPD, in comparison with indacaterol, olodaterol, vilanterol and salmeterol, for both human β_1 - and β_2 -adrenoceptors.

Abediterol association and dissociation rates were monitored directly by using its tritiated form. Moreover, association was determined indirectly using experimental K_i and k_{off} obtained from assays performed with unlabelled compound. Dissociation was also studied indirectly by measuring the association rate of ${}^3\text{H-CGP12177}$ to beta adrenoceptors previously occupied by unlabelled compounds.

Abediterol shows a fast association for the β_2 -adrenoceptor (k_{on} 1.4x10⁷±1.8x10⁶ M⁻¹min⁻¹) while its dissociation rate is between 30 and 64 times slower than that of the reference LABA compounds tested, with a residence time of 91.3±13.3 min (measured directly) and 185.5±7.5 min (measured indirectly). Abediterol shows kinetic selectivity for the β_2 - over the β_1 -

Download English Version:

https://daneshyari.com/en/article/8529664

Download Persian Version:

https://daneshyari.com/article/8529664

<u>Daneshyari.com</u>